MedTrace Logo

Moderate to Persistent Asthma in the Obese Subject

NCT01016847 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2014-11-17

Study results available
· View outcomes & findings →

Summary

Obesity is associated with increased airway inflammation and asthma severity that results in suboptimal control of asthma despite therapy with high dose inhaled corticosteroids (ICS). The investigators suggested that the addition of Singular (montelukast)\[LTRA\] to moderate doses of inhaled corticosteroids will improve asthma control. This cross over study will be treat subjects with moderate dose ICS/LTRA for 12 weeks and high dose ICS with placebo for 12 weeks.

Conditions

Interventions

DRUG

Montelukast

10 mg Q day

OTHER

Sugar pill

Sugar pill that looks like Montelukast that will be given Q day

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01016847 on ClinicalTrials.gov